Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Swiss - Delayed Quote CHF

Addex Therapeutics Ltd (ADXN.SW)

Compare
0.0700
+0.0138
+(24.56%)
At close: February 24 at 5:30:12 PM GMT+1
Currency in CHF All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
556.0450
1,612.9530
1,422.4380
2,916.3080
3,612.8190
Operating Expense
11,633.9910
11,894.3680
21,942.1660
18,422.2220
15,856.0930
Operating Income
-11,077.9460
-10,281.4150
-20,519.7280
-15,505.9140
-12,243.2740
Net Non Operating Interest Income Expense
0.4560
42.3570
-19.6460
-57.6900
-34.1970
Other Income Expense
-1,596.2230
-317.2850
-264.3600
211.6930
-581.1280
Pretax Income
-12,673.5970
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Net Income Common Stockholders
5,404.6870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Diluted NI Available to Com Stockholders
5,404.6870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Basic EPS
0.05
-0.14
-0.46
-0.45
-0.48
Diluted EPS
0.02
-0.14
-0.46
-0.45
-0.48
Basic Average Shares
95,112.3540
74,307.6350
45,184.8650
34,119.6660
26,681.7740
Diluted Average Shares
95,112.3540
74,307.6350
45,184.8650
34,119.6660
26,681.7740
Total Operating Income as Reported
-11,077.8300
-10,281.2990
-20,520.2070
-15,505.9170
-12,243.2740
Rent Expense Supplemental
--
35.5670
47.2830
37.5120
12
Total Expenses
11,633.9910
11,894.3680
21,942.1660
18,422.2220
15,856.0930
Net Income from Continuing & Discontinued Operation
5,404.6870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Normalized Income
-12,483.0560
-10,238.9420
-20,539.8530
-15,563.6070
-12,277.4710
Interest Income
22.3110
63.9640
29.2510
5.3220
35.3050
Interest Expense
21.8550
21.6070
48.8970
63.0120
69.5020
Net Interest Income
0.4560
42.3570
-19.6460
-57.6900
-34.1970
EBIT
-12,651.7420
-10,534.6200
-20,755.3160
-15,288.9020
-12,789.0970
EBITDA
-12,185.7090
-10,228.6680
-20,432.1720
-14,941.2890
-12,410.3430
Reconciled Depreciation
315.7020
305.9520
323.1440
347.6130
378.7540
Net Income from Continuing Operation Net Minority Interest
-12,673.5970
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Total Unusual Items Excluding Goodwill
-190.5410
-317.2850
-264.3600
211.6930
-581.1280
Total Unusual Items
-190.5410
-317.2850
-264.3600
211.6930
-581.1280
Normalized EBITDA
-11,995.1680
-9,911.3830
-20,167.8120
-15,152.9820
-11,829.2150
12/31/2020 - 5/22/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARGX.VI argenx SE
615.60
-0.71%
 
MRNA.VI Moderna, Inc.
32.51
+1.86%
 
EVE.SW Evolva Holding SA
1.1750
-5.24%
 
W1H.F Onco-Innovations Limited
1.8600
+8.14%
 
NWRN.SW Newron Pharmaceuticals S.p.A.
10.22
-0.97%
 
MOLN.SW Molecular Partners AG
4.3200
+0.70%
 
SANN.SW Santhera Pharmaceuticals Holding AG
16.08
0.00%
 
RLF.SW Relief Therapeutics Holding SA
3.1900
-0.93%
 
CSCI COSCIENS Biopharma Inc.
2.8500
+0.71%
 
MEIP MEI Pharma, Inc.
2.6500
+3.11%